10-Q: Ovid Therapeutics Reports First Quarter 2024 Financial Results, Advances Clinical Programs

Ovid Therapeutics reported a net loss of $11.7 million for the first quarter of 2024, while progressing its clinical development programs for OV329 and OV888.

Summary

• Ovid Therapeutics reported a net loss of $11.7 million for the three months ended March 31, 2024, compared to a net loss of $13.4 million for the same period in 2023.
• The company's total revenue for the quarter was $148,000, primarily from license and other revenue.
• Research and development expenses increased to $10.4 million, up from $6.6 million in the prior year, due to the acceleration of clinical development in OV329 and OV888.
• General and administrative expenses decreased to $7.2 million from $8.3 million in the same period last year, due to a reduction in force and strategic cost-reduction initiatives.
• As of March 31, 2024, Ovid had approximately $90.3 million in cash, cash equivalents, and marketable securities.
• The company believes its current cash resources will be sufficient to fund operations for at least the next 12 months.
• Ovid is highly dependent on its ability to find additional sources of funding through equity offerings, debt financings, collaborations, strategic alliances, or licensing agreements.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company is making progress in its clinical programs and has sufficient cash for the next 12 months, it is still incurring significant losses and is dependent on future funding. The increase in R&D expenses and the accumulated deficit are concerning, but the company is actively working to advance its pipeline.

Positives

• The company's cash position of $90.3 million is expected to fund operations for at least the next 12 months.
• General and administrative expenses decreased by $1.2 million due to cost-reduction initiatives.
• The company is progressing its clinical development programs for OV329 and OV888.
• Takeda is progressing the development of soticlestat with regulatory filings expected in Takeda's 2024 fiscal year.

Negatives

• The company reported a net loss of $11.7 million for the quarter.
• Research and development expenses increased significantly to $10.4 million.
• The company is highly dependent on its ability to find additional sources of funding.
• The company has an accumulated deficit of $289.6 million as of March 31, 2024.

Risks

• The company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including development and regulatory success.
• The company is dependent on its ability to secure additional capital to fund operations.
• The company faces risks associated with delays or problems in the supply of product candidates, loss of single-source suppliers, and failure to comply with manufacturing regulations.
• The company is subject to risks associated with identifying, acquiring, or in-licensing additional products or product candidates.
• The company faces risks associated with pharmaceutical product development and the inherent uncertainty of clinical success.
• The company is subject to risks associated with protecting and enhancing intellectual property rights and complying with applicable regulatory requirements.
• The company is subject to risks associated with obtaining regulatory approval of any of its product candidates.
• The global economic slowdown, bank failures, public health crises, and geopolitical tensions may have a material adverse effect on the company's business.
• Rising interest rates could make it more difficult for the company to obtain traditional financing on acceptable terms.
• Inflationary factors may adversely affect the company's operating results.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for at least the next several years. Management believes that the company's existing cash, cash equivalents, and marketable securities will be sufficient to fund its current operating plans through at least the next 12 months. The company expects to submit an IND application to begin clinical trials for a third program in the second half of 2024.

Management Comments

• Management believes that the company's existing cash, cash equivalents and marketable securities as of March 31, 2024 will be sufficient to fund its current operating plans through at least the next 12 months from the date of filing of the Companys Quarterly Report on Form 10-Q.
• The company is highly dependent on its ability to find additional sources of funding through either equity offerings, debt financings, collaborations, strategic alliances, licensing agreements or a combination of any such transactions.

Industry Context

Ovid Therapeutics is operating in the competitive biopharmaceutical industry, focusing on rare epilepsies and neurological disorders. The company's progress in clinical trials and strategic collaborations are key to its future success. The company is also subject to the broader economic and market conditions affecting the pharmaceutical and biotechnology sectors.

Comparison to Industry Standards

• Ovid's R&D spending is typical for a clinical-stage biotech company, with a focus on advancing its pipeline.
• The company's reliance on external funding is common in the biotech industry, especially for companies without commercial products.
• The company's net loss is consistent with other development-stage biotech companies that are investing heavily in R&D.
• The company's cash runway of 12 months is a standard benchmark for biotech companies, indicating a need for future capital raises.
• The company's focus on rare diseases aligns with a trend in the industry towards developing treatments for underserved patient populations.
• The company's reliance on third-party manufacturers and CROs is a common practice in the biotech industry to manage costs and leverage expertise.

Legal Proceedings

• The company is currently defending a post grant review (PGR) action initiated by Marinus, challenging one of the company's patents related to the use of ganaxolone for the treatment of status epilepticus.
• The company initiated an inter partes review (IPR) to challenge Marinus's later filed patent related to the use of ganaxolone for the treatment of status epilepticus.

Related Party Transactions

• In March 2021, the company entered into the RLT Agreement with Takeda.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• Employees may be affected by potential reorganizations or changes in the company's strategy.
• Patients may benefit from the development of new treatments for epilepsies and neurological disorders.
• Suppliers and collaborators may be impacted by the company's financial performance and strategic decisions.
• Creditors may be affected by the company's ability to secure additional funding.

Next Steps

• The company expects to submit an IND application to begin clinical trials for a third program in the second half of 2024.
• Ovid and Graviton intend to initiate a signal-finding trial in people living with cerebral cavernous malformations in the second half of 2024.
• The current Phase 1 study for OV329 is expected to be completed in the second half of 2024.
• An IND application or the equivalent for the IV formulation of OV329 is expected in the second half of 2024.
• An IV formulation of OV350 is progressing toward an anticipated IND in the second half of 2024.

Key Dates

Keywords

biopharmaceutical, epilepsy, seizures, OV329, OV888, soticlestat, clinical trials, drug development, licensing, neurological disorders, GABA-aminotransferase inhibitor, KCC2 transporter, ROCK2 inhibitors